• Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=8562478).
  

PubMed=8562478
Katja Wosikowski, Joanna T. Regis, Robert W. Robey, Manuel Alvarez, Jeroen Titus Maria Buters, Jean Marie Gudas, Susan E. Bates;
Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Cell Growth Differ. 6:1395-1403(1995)

PubMed=9815641
Katja Wosikowski, Danita H. Schuurhuis, Geert J.P.L. Kops, Miguel Saceda, Susan E. Bates;
Altered gene expression in drug-resistant human breast cancer cells.
Clin. Cancer Res. 3:2405-2414(1997)

PubMed=10995814; DOI=10.1093/jnci/92.18.1535
Farzaneh Pirnia, Madlaina Breuleux, Erasmus Schneider, Manfred Hochmeister, Susan E. Bates, Andreas Marti, Michel-Andre Hotz, Daniel C. Betticher, Markus M. Borner;
Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53.
J. Natl. Cancer Inst. 92:1535-1536(2000)

PubMed=14871996; DOI=10.1158/1078-0432.CCR-1044-3
Yan-Ping Hu, Awtar Krishan, Wei-Jia Nie, Kasi S. Sridhar, Lawrence D. Mayer, Marcel Bally;
Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
Clin. Cancer Res. 10:1160-1169(2004)